Retatrutide clears fatty liver in 85%+ of patients, cagrilintide posts Phase 3 obesity results, and Lilly investigates GLP-1s for substance use disorders.
10 stories · Covering research, clinical-trials, regulatory, industry
Today's peptide landscape is led by a wave of retatrutide clinical data — Eli Lilly's triple-agonist now shows it can clear fatty liver disease in over 85% of patients, on top of exceptional weight loss. Cagrilintide, Novo Nordisk's amylin analog, posted promising Phase 3 monotherapy results for obesity, carving out a new mechanistic approach. Meanwhile, Eli Lilly and Baseline Therapeutics are investigating GLP-1s for substance use disorders — a potentially massive new therapeutic frontier. On the regulatory front, the FDA is considering relaxing dietary supplement warning label rules, while the debate over peptide safety and access continues to intensify globally.
Findings presented at The Liver Meeting show retatrutide cleared fatty liver disease in more than 85% of patients with obesity, dramatically expanding its therapeutic profile beyond weight loss.
Detailed Phase 3 results for Eli Lilly's triple-agonist (GLP-1/GIP/glucagon) showed significant weight loss alongside improved pain and physical function in obesity-related knee osteoarthritis. Seven additional Phase 3 trials underway.
Lilly and startup Baseline Therapeutics are investigating GLP-1 RAs for alcohol and substance use disorders. A large VA study found GLP-1s associated with reduced substance abuse risk, in a therapeutic area projected to reach $12.4B by 2033.
Novo Nordisk's amylin analog peptide showed significant weight loss as standalone treatment in Phase 3 trial data, positioning it as a new pillar in peptide-based obesity treatment.
The FDA approved once-daily oral semaglutide (Wegovy) 25 mg as the first GLP-1 pill for weight loss, offering a convenient alternative to injections with comparable weight loss to the original injection.
CancerNetwork reviews the latest evidence on thyroid cancer risk associated with GLP-1 RAs like Ozempic and Mounjaro, providing clinicians with an updated risk-benefit assessment for long-term prescribing.
GLP-1 RAs, particularly semaglutide, are showing robust clinical data for liver disease with significant rates of disease resolution and improvement in liver fibrosis.
The thymus — source of thymosin peptides including Thymosin Alpha-1 — has become an emerging target for healthspan, longevity, and precision oncology research.
The FDA is evaluating potential changes to dietary supplement warning label requirements, with pharmacists urged to remain vigilant as regulations may loosen under the current administration.
Investigation into the unregulated peptide market noting how easily BPC-157 can be purchased online with next-day delivery, amid celebrity endorsements from Joe Rogan and growing safety concerns.